/
Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, Provectus or the Company ), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases. Our drug product candidates are based on bioactive, synthetic, small molecule rose bengal sodium ( RBS ), which is a member of a class of molecules called halogenated xanthenes…
The business is unprofitable at the operating level (-1575.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 45.5% YoY. Margins deteriorated 840.9pp alongside, both lines moving the wrong way.
Negative free cash flow of -$3M. The business is consuming cash, not generating it. Operating margin contracted 840.9pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (FY)
$336K
▼ -45.5% YoY
Net Income (TTM)
-$6M
▼ -14.8% YoY
Op. Margin
-1575.32%
▼ -840.9pp YoY
ROIC
-198.48%
▲ +417.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▼ -1.3% YoY
Op. Cash Flow (TTM)
-$3M
▼ -1.3% YoY
Net Debt
$3M
Cash & Equiv.
$224K
3Y CAGR: -30.2%
Continue Research